Pharmacogenomics — MCQs

Pharmacogenomics Indian Medical PG Practice Questions and MCQs

Question 21: Which of the following terms best describes a drug that blocks the action of adrenaline at its receptors by occupying those receptors without activating them?

A. Pharmacologic antagonist (Correct Answer)
B. Non-competitive antagonist
C. Physiologic antagonist
D. Chemical antagonist

Explanation: ### Explanation **1. Why Option A is Correct:** A **pharmacologic antagonist** is a drug that binds to the same receptor as an agonist (in this case, adrenaline) but does not activate it. By occupying the receptor site, it prevents the agonist from binding and exerting its effect. This is the classic definition of receptor-level blockade. Since it competes for the same binding site, it is also often referred to as a competitive antagonist. **2. Why the Other Options are Incorrect:** * **B. Non-competitive antagonist:** These drugs do not simply "occupy" the receptor site to block the agonist; they either bind irreversibly to the active site or bind to an **allosteric site**, changing the receptor's shape so the agonist cannot trigger a response. Unlike pharmacologic antagonists, their effect cannot be overcome by increasing agonist concentration. * **C. Physiologic antagonist:** This refers to two drugs acting on **different receptors** to produce opposite effects in the same system. *Example:* Histamine (bronchoconstriction via H1) vs. Adrenaline (bronchodilation via β2). * **D. Chemical antagonist:** This involves a direct chemical reaction between two substances in solution, neutralizing the drug before it reaches a receptor. *Example:* Protamine sulfate neutralizing Heparin. **3. NEET-PG High-Yield Pearls:** * **Competitive Antagonism:** Shifts the Dose-Response Curve (DRC) to the **right** (increases $EC_{50}$), but the **maximal efficacy ($E_{max}$) remains unchanged**. * **Non-competitive Antagonism:** Flattens the DRC, **decreasing the $E_{max}$**, while the $EC_{50}$ usually remains the same. * **Inverse Agonist:** Binds to the same receptor as an agonist but produces an effect **opposite** to that of the agonist (e.g., Beta-carbolines at GABA receptors).

Question 22: Which of the following statements about a placebo is true?

A. It has pharmacodynamic activity.
B. It is the active moiety of the tablet.
C. It produces the same effect in all patients.
D. It is an inert substance. (Correct Answer)

Explanation: ### Explanation **1. Why Option D is Correct:** A **placebo** (Latin for "I shall please") is defined as an **inert substance** or dummy medication that has no specific pharmacological activity against the condition being treated. It is typically composed of inactive ingredients like lactose, starch, or saline [1]. The "placebo effect" refers to the psychological or non-specific physiological improvement observed in a patient due to their expectation of healing or the act of receiving treatment, rather than the substance itself. **2. Why the Other Options are Incorrect:** * **Option A:** Placebos lack **pharmacodynamic activity** because they do not interact with specific receptors or enzymes to alter physiological functions [2]. Any observed change is psychogenic. * **Option B:** The **active moiety** is the part of a drug molecule responsible for its therapeutic effect. Since placebos are chemically inactive, they contain no active moiety. * **Option C:** The placebo effect is highly subjective and **variable**. It does not produce the same effect in all patients; factors like the patient’s personality, the doctor’s communication style, and the color/route of the placebo influence the outcome. **3. NEET-PG High-Yield Pearls:** * **Clinical Trials:** Placebos are primarily used as "controls" in Randomized Controlled Trials (RCTs) to distinguish the true pharmacologic effect of a new drug from the psychological effects of treatment [1, 3]. * **Nocebo Effect:** This is the "evil twin" of the placebo effect, where a patient experiences worsening symptoms or side effects due to negative expectations. * **Ethics:** In modern medicine, using a placebo when an effective standard treatment exists is generally considered unethical (Declaration of Helsinki).

Question 23: What is the main concern in drug designing?

A. Decreasing binding affinity of drug to target protein
B. Increasing binding affinity of drug to non-target protein
C. Increasing the number of interactions of drug with target protein (Correct Answer)
D. Decreasing the potency of the drug

Explanation: **Explanation:** In drug design, the primary objective is to create a molecule that binds specifically and strongly to its intended biological target (receptor, enzyme, or ion channel) [1]. **Why Option C is Correct:** The strength of the drug-receptor complex is determined by the **number and nature of chemical interactions** (such as hydrogen bonds, van der Waals forces, and ionic bonds) between the drug and the target protein [4]. By **increasing the number of interactions**, the binding affinity and selectivity are enhanced [1]. This ensures that the drug remains bound to the target long enough to elicit a therapeutic effect, thereby increasing **potency** and reducing the dose required [3]. **Why the other options are incorrect:** * **Option A:** Decreasing binding affinity would make the drug less effective, requiring higher doses and increasing the risk of dissociation before a response is triggered. * **Option B:** Increasing affinity for non-target proteins leads to **"off-target effects,"** which are the primary cause of drug toxicity and side effects [1]. * **Option D:** The goal of drug design is to *increase* potency (the amount of drug needed to produce an effect), not decrease it [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Pharmacogenomics** focuses on how genetic variations (SNPs) affect drug response. A change in the amino acid sequence of a target protein can alter the "number of interactions," leading to drug resistance (e.g., BCR-ABL mutations in CML). * **Structure-Activity Relationship (SAR):** The study of how modifying a drug’s chemical structure changes its biological activity [2], [3]. * **Covalent bonds** are the strongest drug-receptor interactions and are usually irreversible (e.g., Aspirin binding to COX, Phenoxybenzamine to alpha-receptors) [4].

Question 24: Botulinum toxin acts by:

A. Presynaptic release of acetylcholine
B. Presynaptic inhibition of release of acetylcholine (Correct Answer)
C. GABA mimetic
D. GABA antagonist

Explanation: **Explanation:** Botulinum toxin, produced by the bacterium *Clostridium botulinum*, is a potent neurotoxin that causes flaccid paralysis by targeting the neuromuscular junction. **Mechanism of Action (Why B is correct):** The toxin acts as a zinc-dependent endopeptidase. Once internalized into the presynaptic nerve terminal, it cleaves **SNARE proteins** (specifically SNAP-25, synaptobrevin, or syntaxin). These proteins are essential for the docking and fusion of acetylcholine-containing vesicles with the presynaptic membrane. By destroying these proteins, the toxin prevents the exocytosis of acetylcholine into the synaptic cleft, leading to **presynaptic inhibition of acetylcholine release**. **Analysis of Incorrect Options:** * **Option A:** This describes the mechanism of certain spider venoms (like Black Widow venom/α-latrotoxin), which cause massive neurotransmitter release, leading to muscle spasms. * **Options C & D:** Botulinum toxin acts specifically on cholinergic (acetylcholine) transmission at the peripheral neuromuscular junction and autonomic ganglia. It does not have a direct mechanism involving GABA, which is the primary inhibitory neurotransmitter in the Central Nervous System (CNS). **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Presentation:** Causes "Floppy Baby Syndrome" (infant botulism via honey ingestion) and symmetric descending paralysis. * **Therapeutic Uses:** Used for focal dystonias (e.g., blepharospasm, torticollis), achalasia cardia, hyperhidrosis, and cosmetic reduction of wrinkles. * **Contrast with Tetanus Toxin:** While both cleave SNARE proteins, Tetanus toxin undergoes retrograde axonal transport to the CNS and inhibits **GABA/Glycine** release from Renshaw cells, causing spastic paralysis.

Question 25: All drugs are metabolized by acetylation EXCEPT:

A. Phenytoin (Correct Answer)
B. Isoniazid
C. Procainamide
D. Hydralazine

Explanation: ### Explanation The correct answer is **Phenytoin**. **1. Underlying Medical Concept: Acetylation** Acetylation is a **Phase II metabolic reaction** catalyzed by the enzyme **N-acetyltransferase (NAT)**. This pathway is genetically determined, leading to the classification of individuals as "fast acetylators" or "slow acetylators." **Phenytoin** is primarily metabolized by **Phase I oxidation** (hydroxylation) via the cytochrome P450 system, specifically **CYP2C9** and **CYP2C19**. It does not undergo acetylation. Phenytoin also follows zero-order kinetics at high therapeutic concentrations, making its metabolism easily saturable. **2. Analysis of Incorrect Options** The other three drugs are classic examples of drugs metabolized by acetylation. A helpful mnemonic to remember these is **SHIP**: * **S**ulfonamides * **H**ydralazine (Option D) * **I**soniazid (Option B) * **P**rocainamide (Option C) **3. Clinical Pearls for NEET-PG** * **Drug-Induced Lupus Erythematosus (DILE):** Slow acetylators are at a significantly higher risk of developing DILE when taking Hydralazine, Procainamide, or Isoniazid because the drugs persist longer in the body. * **Isoniazid Toxicity:** Slow acetylators are more prone to peripheral neuropathy (due to Vitamin B6 deficiency), while fast acetylators may be more prone to isoniazid-induced hepatotoxicity (due to rapid conversion to acetyl-hydrazine). * **Genetic Polymorphism:** The NAT2 gene is the most clinically relevant polymorphic gene governing acetylation rates in humans. * **Phenytoin Side Effects:** Remember the mnemonic **HOT MALAI** (Hirsutism, Osteomalacia, Teratogenicity, Megaloblastic anemia, Ataxia, Lymphadenopathy, Arrhythmias, Insulin inhibition).

Question 26: Glucagon acts via which second messenger system?

A. cAMP (Correct Answer)
B. cGMP
C. Cytoplasmic Ca+
D. Intracellular K+

Explanation: **Explanation:** Glucagon is a peptide hormone produced by the alpha cells of the pancreas. It exerts its primary metabolic effects by binding to specific **G Protein-Coupled Receptors (GPCRs)** on the surface of hepatocytes. 1. **Why cAMP is correct:** When glucagon binds to its receptor, it activates the **Gs (stimulatory) protein**, which in turn stimulates the enzyme **Adenylyl Cyclase**. This enzyme converts ATP into **cyclic AMP (cAMP)**. Increased levels of cAMP activate **Protein Kinase A (PKA)**, leading to the phosphorylation of key enzymes that promote glycogenolysis and gluconeogenesis while inhibiting glycogenesis. 2. **Why other options are incorrect:** * **cGMP:** This is the second messenger for Atrial Natriuretic Peptide (ANP) and Nitric Oxide (NO), primarily involved in vasodilation. * **Cytoplasmic Ca²⁺:** This is typically associated with the **Gq pathway** (via IP3/DAG), used by hormones like Oxytocin, Vasopressin (V1 receptors), and α1-adrenergic agonists. * **Intracellular K⁺:** While ion channels are involved in insulin secretion (ATP-sensitive K+ channels), they do not serve as the primary second messenger for glucagon signaling. **High-Yield Clinical Pearls for NEET-PG:** * **Glucagon in Beta-blocker Overdose:** Glucagon is the **antidote of choice** for beta-blocker poisoning. It bypasses blocked beta-receptors to increase cAMP directly in cardiac myocytes, exerting positive inotropic and chronotropic effects. * **Other cAMP users:** Remember the mnemonic "FLAT ChAMP" (FSH, LH, ACTH, TSH, CRH, hCG, ADH (V2), MSH, PTH, and Glucagon). * **Insulin vs. Glucagon:** While Glucagon uses cAMP, **Insulin** uses a **Receptor Tyrosine Kinase** pathway.

Question 27: Pharmacodynamics deals with which of the following?

A. The effect of drugs on the body. (Correct Answer)
B. The effect of the body on drugs.
C. Absorption of drugs.
D. Metabolism of drugs.

Explanation: **Explanation:** **Pharmacodynamics** is defined as the study of the biochemical and physiological effects of drugs and their mechanisms of action. In simple terms, it describes **"what the drug does to the body."** This includes drug-receptor interactions, signal transduction pathways, and the resulting therapeutic or toxic effects. **Analysis of Options:** * **Option A (Correct):** This is the literal definition of pharmacodynamics. It focuses on the drug's efficacy, potency, and physiological impact. * **Option B (Incorrect):** This describes **Pharmacokinetics**, which is the study of **"what the body does to the drug."** * **Options C & D (Incorrect):** Absorption and Metabolism are two of the four primary components of pharmacokinetics (often remembered by the acronym **ADME**: Absorption, Distribution, Metabolism, and Excretion). **NEET-PG High-Yield Pearls:** 1. **Mnemonic:** Remember **D**ynamics = **D**rug does to body; **K**inetics = Body does to drug (**K**inetics involves movement). 2. **Pharmacogenomics Connection:** While pharmacokinetics deals with how genes affect drug metabolism (e.g., CYP450 polymorphisms), **pharmacodynamic variation** involves genetic differences in drug targets, such as receptors or enzymes (e.g., VKORC1 polymorphisms affecting Warfarin sensitivity). 3. **Key Parameters:** Pharmacodynamics is measured using Dose-Response Curves (DRC), looking at parameters like $ED_{50}$ (Potency) and $E_{max}$ (Efficacy). 4. **Receptors:** Most pharmacodynamic effects are mediated through four receptor families: Ion channels, G-protein coupled receptors (GPCRs), Enzymatic receptors, and Nuclear receptors.

Question 28: Which of the following drugs can cause drug-induced lupus erythematosus, particularly in individuals with slow N-acetyltransferase activity?

A. Propranolol
B. Hydralazine (Correct Answer)
C. Digoxin
D. Captopril

Explanation: **Explanation:** The correct answer is **Hydralazine**. This question tests the concept of **Pharmacogenomics**, specifically the role of the **N-acetyltransferase (NAT2)** enzyme in drug metabolism. **1. Why Hydralazine is correct:** Hydralazine is metabolized in the liver via **Phase II Acetylation**. The population is genetically divided into "Fast Acetylators" and "Slow Acetylators." In **Slow Acetylators**, the drug remains in the systemic circulation for a longer duration at higher concentrations. This prolonged exposure promotes the formation of antinuclear antibodies (ANA), leading to **Drug-Induced Lupus Erythematosus (DILE)**. **2. Why other options are incorrect:** * **Propranolol:** A beta-blocker primarily metabolized by CYP2D6 and CYP1A2. It is not associated with DILE or NAT2 activity. * **Digoxin:** A cardiac glycoside primarily excreted unchanged by the kidneys (P-glycoprotein substrate). It does not undergo acetylation. * **Captopril:** An ACE inhibitor that contains a sulfhydryl group. While it can rarely cause skin rashes or neutropenia, it is not metabolized by NAT2 and is not a classic cause of DILE. **3. NEET-PG High-Yield Pearls:** * **Mnemonic for DILE drugs (SHIP):** **S**ulfonamides, **H**ydralazine, **I**soniazid, **P**rocainamide. * **Procainamide** carries the highest risk of inducing DILE, but **Hydralazine** is the most frequently cited in the context of slow acetylation. * **Clinical Distinction:** Unlike systemic lupus (SLE), DILE usually spares the kidneys and CNS, and symptoms typically resolve upon drug discontinuation. * **Serological Marker:** **Anti-histone antibodies** are present in >95% of DILE cases (Highly specific). Anti-dsDNA is usually negative.

Question 29: All of the following statements regarding volume of distribution are true except?

A. Half-life is usually proportional to Vd.
B. It is calculated by multiplying the half-life by log base 2. (Correct Answer)
C. Skeletal muscle relaxants generally have a low volume of distribution.
D. Drugs with high plasma protein binding tend to have a low volume of distribution.

Explanation: **Explanation** **Why Option B is Correct:** The statement is mathematically incorrect. The Volume of Distribution ($V_d$) is calculated using the formula: **$V_d = \text{Dose} / \text{Plasma Concentration}$**. The relationship involving half-life ($t_{1/2}$) is actually: **$t_{1/2} = 0.693 \times V_d / \text{Clearance (CL)}$**. While $0.693$ is the natural log of 2 ($\ln 2$), $V_d$ is not derived by simply multiplying half-life by $\log_2$. Instead, $V_d$ is a primary pharmacokinetic parameter determined by the physical properties of the drug and the body, whereas half-life is a secondary parameter derived from $V_d$ and Clearance. **Analysis of Other Options:** * **Option A:** True. Since $t_{1/2} \propto V_d$, a larger volume of distribution (meaning the drug is sequestered in tissues) results in a longer half-life because the drug is less available for elimination by the liver or kidneys. * **Option C:** True. Skeletal muscle relaxants (e.g., Atracurium, Succinylcholine) are highly ionized, polar molecules. They do not cross cell membranes easily and remain largely confined to the extracellular fluid/plasma, resulting in a low $V_d$. * **Option D:** True. Drugs that bind extensively to plasma albumin (e.g., Warfarin) stay within the vascular compartment. Since $V_d = \text{Amount in body} / \text{Plasma concentration}$, a high plasma concentration leads to a low $V_d$. **High-Yield Clinical Pearls for NEET-PG:** * **Loading Dose:** $V_d$ is the primary determinant of the loading dose ($\text{LD} = V_d \times \text{Target Plasma Concentration}$). * **Hemodialysis:** Drugs with a very high $V_d$ (e.g., Digoxin, Chloroquine, TCAs) cannot be effectively removed by hemodialysis because they reside mostly in tissues, not the blood. * **Total Body Water:** If $V_d$ exceeds the total body water (~42L), it indicates the drug is highly sequestered in specific tissues (like fat or bone).

Question 30: Pharmacovigilance is a branch of pharmacology concerned with:

A. Monitoring of drugs
B. Adverse effects of drugs (Correct Answer)
C. Drug dosing
D. Drug clearance

Explanation: **Explanation:** **Pharmacovigilance (PV)** is defined by the World Health Organization (WHO) as the science and activities relating to the **detection, assessment, understanding, and prevention of adverse effects** or any other drug-related problems. Its primary goal is to ensure patient safety by identifying previously unrecognized adverse drug reactions (ADRs) after a drug has been released into the market (Phase IV clinical trials) [1]. * **Why Option B is correct:** The core mandate of pharmacovigilance is the systematic monitoring of **adverse effects**. It involves the collection of data regarding ADRs to determine the risk-benefit ratio of medications in the general population [2]. This system provides early warning signals of unexpected adverse effects that can then be investigated [1]. * **Why Option A is incorrect:** While "monitoring" is part of the process, it is too vague. Pharmacovigilance specifically monitors *safety outcomes* rather than therapeutic drug monitoring (TDM) or general drug usage patterns. * **Why Options C & D are incorrect:** Drug dosing and clearance are components of **Pharmacokinetics** (what the body does to the drug). While dosing may be adjusted based on PV data, these terms describe the physiological handling of a drug rather than the surveillance of its safety profile [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Phase IV Clinical Trials:** Pharmacovigilance is synonymous with Post-Marketing Surveillance [1]. * **Uppsala Monitoring Centre (UMC):** Located in Sweden, it is the international headquarters for global ADR monitoring. * **Pharmacovigilance Programme of India (PvPI):** The national coordination center is the **Indian Pharmacopoeia Commission (IPC)**, Ghaziabad. * **Vigiflow:** The software used for reporting ADRs in India. * **Spontaneous Reporting:** The most common method used in pharmacovigilance for identifying rare or delayed adverse effects [1].

Practice by Chapter

Genetic Basis of Drug Response

Practice Questions

Pharmacogenomic Testing

Practice Questions

Cytochrome P450 Polymorphisms

Practice Questions

Pharmacogenomics of Drug Transporters

Practice Questions

Pharmacogenomics in Oncology

Practice Questions

Pharmacogenomics in Cardiovascular Therapeutics

Practice Questions

Pharmacogenomics in Psychiatry

Practice Questions

Personalized Medicine Approaches

Practice Questions

Ethical Considerations in Pharmacogenomics

Practice Questions

Implementation of Pharmacogenomics in Clinical Practice

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free